9 research outputs found
Optimal management of constipation associated with irritable bowel syndrome
Irritable bowel syndrome (IBS) is a common chronic functional disorder of the gastrointestinal tract, meanly characterized by recurrent abdominal pain or discomfort and altered bowel habit. It is a complex disorder involving biological, environmental, and psychosocial factors. The diagnosis is achieved according to the Rome III criteria provided that organic causes have been excluded. Although IBS does not constitute a life-threatening condition, it has a remarkable prevalence and profoundly reduces the quality of life with burdening socioeconomic costs. One of the principal concerns about IBS is the lack of effective therapeutic options. Up to 40% of patients are not satisfied with any available medications, especially those suffering from chronic constipation. A correct management of IBS with constipation should evolve through a global approach focused on the patient, starting with careful history taking in order to assess the presence of organic diseases that might trigger the disorder. Therefore, the second step is to examine lifestyle, dietary habits, and psychological status. On these bases, a step-up management of disease is recommended: from fiber and bulking agents, to osmotic laxative drugs, to new molecules like lubiprostone and linaclotide. Although new promising tools for relief of bowel-movement-related symptoms are being discovered, a dedicated doctor-patient relationship still seems to be the key for success
Prevalence of active H. pylori infection and clarithromycin-contatining triple therapy efficacy in patients with dyspepsia-experience of a tertiary centre in North of Italy
Positive PET in a patient with esophageal leiomyoma.
reserved8mixedDel Nero, L; Moscatelli, A; Fazio, V; Pellegatta, G; Bongioanni, F; Sambuceti, G; Savarino, V; Giannini, Eg.DEL NERO, Lorenzo; Moscatelli, Alessandro; Fazio, Valentina; Pellegatta, G; Bongioanni, Francesca; Sambuceti, Gianmario; Savarino, Vincenzo; Giannini, EDOARDO GIOVANN
Su1208 Prevalence of Active H. pylori Infection and Clarithromycin-Containing Triple Therapy Efficacy in Patients With Dyspepsia -Experience of a Tertiary Centre in North of Italy
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
Background & Aims: Loss of response to anti-tumor necrosis factor (TNF) drugs in patients with inflammatory
bowel disease is likely due to low drug serum levels, and dosing anti-TNF drug concentrations may improve
patients\u2019 outcome. However, there are limited data on the diagnostic accuracy and utility of currently available
assays for measuring anti-TNF levels. In this study, our aim was to compare serum adalimumab concentrations
with two different techniques.
Methods: We assessed serum adalimumab concentrations in 23 patients with Crohn\u2019s disease during a 96-week
follow-up period. Adalimumab trough levels were assessed using a sandwich principle-based enzyme-linked
immunosorbent assay (ELISA) and a homogeneous mobility shift assay (HMSA).
Results: At week 48, adalimumab trough levels were significantly lower in patients who experienced relapse
compared to patients in remission, using both ELISA and HMSA methods: 4.8 mcg/mL (2.4-7.2 mcg/mL)
vs. 7.5 mcg/mL (6.6-8.4 mcg/mL) (P=0.01) and 6.5 mcg/mL (3-10 mcg/mL) vs. 11.6 mcg/mL (7-16.2 mcg/
ml) (P=0.004), respectively. Similar results were obtained at week 96: 5.9 mcg/mL (3.3-8.5 mcg/mL) vs. 12.8
mcg/mL (9.4-16.2 mcg/mL) (P=0.001) and 4.1 mcg/mL (1.6-6.6 mcg/mL) vs. 7.5 mcg/mL (5.7-9.3 mcg/mL)
(P=0.009), respectively. There was a significant correlation between ELISA and HMSA adalimumab trough
levels at both 48 (r = 0.691, P=0.0003) and 96 week (r = 0.822, P=0.0001).
Conclusions: ELISA and HMSA assays are accurate methods to assess adalimumab trough levels in patients
with Crohn\u2019s disease and those who experience loss of response. The preferential use of one of the two
techniques should be based on local availability and physicians\u2019 experience
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease
Background: The use of therapeutic drug monitoring has been proposed as a useful tool in the management of patients with loss of response to biological therapy in patients with inflammatory bowel disease. Aims: To evaluate whether early, post-induction anti-tumor necrosis factor trough levels and the presence of different types of anti-drug antibodies may impact long-term clinical remission in patients with inflammatory bowel disease. Methods: We prospectively assessed anti-tumor necrosis factor trough levels and both persistent and transient anti-drug antibodies. The Harvey-Bradshaw Index and the partial Mayo score were evaluated at each visit or in case of relapse. Results: At week 14, median infliximab trough levels were significantly lower in patients who experienced loss of response at week 48 as compared to patients in stable remission (1.3. mcg/mL [range 0-10.2. mcg/mL] vs. 10.1. mcg/mL[range 0-42.8. mcg/mL], P< 0.0004). ROC curve identified an infliximab trough levels of 6.2. mcg/mL as the cut-off value with the highest accuracy (c-index = 0.864) for loss of response at week 48. At week 14 we observed a correlation between anti-drug antibodies concentration and infliximab trough levels (rs= -0.513, P = 0.04). Conclusions: The results highlight the usefulness of assessing early biological TL in order to predict patients' long-term outcome
Notulae to the Italian native vascular flora: 12
In this contribution, new data concerning the distribution of native vascular flora in Italy are presented. It
includes new records, confirmations, exclusions, and status changes to the Italian administrative regions. Nomenclatural
and distribution updates, published elsewhere, and corrigenda are provided as Suppl. material 1